Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 6:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 72 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ECG Effects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women

NCT00360425
View directory record Official record
Conditions
Anemia
Interventions
ferumoxytol, moxifloxacin, placebo
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 18, 2026, 6:34 PM EDT
Withdrawn Not applicable Interventional

Effects of CRT Optimization as Assessed by Cardiac MR

NCT04763460
View directory record Official record
Conditions
Heart Failure, Systolic
Interventions
Programming of CRT device settings
Device
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 18, 2026, 6:34 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor

NCT06699056
View directory record Official record
Conditions
Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement, Conduction Defect, Heart Failure, Valvular Heart Disease, Ischemic Heart Disease, Cardiotoxicity, Myocardial Infarction, Dilated Cardiomyopathy, HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Syncope, Remodeling, Cardiac
Interventions
15-minutes of sitting during COR ECG Acquistion
Device
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
8
States / cities
Orange, California • Pasadena, California • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 18, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

NCT06422767
View directory record Official record
Conditions
Hepatitis B
Interventions
Bepirovirsen, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 18, 2026, 6:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acute Effects of Organic Guayusa Extract

NCT05928195
View directory record Official record
Conditions
Acute Physiological Effects of Organic Guayusa Extract
Interventions
Acute Moderate-Dose Guayusa Extract Supplementation, Acute High-Dose Guayusa Extract Supplementation, Placebo
Dietary Supplement
Lead sponsor
Nathaniel Jenkins
Other
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 18, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants

NCT05988034
View directory record Official record
Conditions
Electrocardiography
Interventions
Avacopan, Moxifloxacin, Placebo for avacopan, Placebo for moxifloxacin
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 18, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Thorough QT Study of Telotristat Etiprate

NCT02155205
View directory record Official record
Conditions
QT Interval
Interventions
Telotristat etiprate, Placebo, Moxifloxacin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 18, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Cardiac Effects of ALXN1840 in Healthy Adults

NCT04560816
View directory record Official record
Conditions
Healthy
Interventions
ALXN1840, Placebo, Moxifloxacin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 18, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

CAEB071 Thorough QTc Study in Healthy Volunteers

NCT01594255
View directory record Official record
Conditions
Healthy
Interventions
sotrastaurin, placebo to sotrastaurin, Avelox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Oct 18, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers

NCT02257398
View directory record Official record
Conditions
Infections, Respiratory Tract
Interventions
GSK2140944, GSK2140944 placebo, Moxifloxacin, Moxifloxacin placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 18, 2026, 6:34 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Objective Assessment of the Effects of Shift Work on Drowsiness and Driving Impairment in Hospital Staff

NCT01672489
View directory record Official record
Conditions
Impaired Driving, Sleep Driving
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 18, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers

NCT00699504
View directory record Official record
Conditions
Healthy
Interventions
cangrelor, moxifloxacin, placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 18, 2012 · Synced Oct 18, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Thorough EKG Safety Study of TA-1790 (Avanafil)

NCT00769041
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
moxifloxacin, avanafil, sugar pill
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 7, 2011 · Synced Oct 18, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants

NCT02152332
View directory record Official record
Conditions
Healthy
Interventions
JNJ-54861911-Therapeutic Dose, JNJ-54861911 - Supratherapeutic Dose, JNJ-54861911-Matched Placebo, Moxifloxacin, Moxifloxacin Matched Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 18, 2026, 6:34 PM EDT
Completed Phase 1 Interventional

A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.

NCT04369391
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP363856 150 mg, Placebo, moxifloxacin 400 mg
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
7
States / cities
Little Rock, Arkansas • Long Beach, California • Pico Rivera, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 18, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Cardiac Effects of ALXN2050 in Healthy Adults

NCT04660890
View directory record Official record
Conditions
Healthy
Interventions
ALXN2050, ALXN2050-matching Placebo, Moxifloxacin, Moxifloxacin-matching Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 18, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects

NCT01297062
View directory record Official record
Conditions
Healthy Subjects
Interventions
Exenatide, Moxifloxacin, Placebo comparator
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 18, 2026, 6:34 PM EDT
Completed No phase listed Observational

Effects Rapid Atrial Pacing Has on the Electrocardiogram (ECG) in Patients With Dual Chamber Pacemakers

NCT00883610
View directory record Official record
Conditions
Prolonged QT Interval
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 18, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

NCT02027454
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1265744, GSK1265744 matching placebo, Moxifloxacin
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Oct 18, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)

NCT03606057
View directory record Official record
Conditions
Healthy
Interventions
JNJ-64565111, Moxifloxacin, JNJ-64565111-matching Placebo, Moxifloxacin-matching Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
188 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 18, 2026, 6:34 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Odiparcil QT Definitive Study

NCT00437242
View directory record Official record
Conditions
Fibrillation, Atrial, Atrial Fibrillation
Interventions
Odiparcil
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 18, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects

NCT01913002
View directory record Official record
Conditions
Healthy
Interventions
LX4211 800 mg, LX4211 2000 mg, moxifloxacin 400 mg, LX4211 Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Oct 18, 2026, 6:34 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic & Pharmacodynamic Interaction of Lofexidine and Buprenorphine in Buprenorphine Maintained Patients

NCT01820442
View directory record Official record
Conditions
Opioid Dependence, Buprenorphine Withdrawal Syndrome
Interventions
Lofexidine HCl, Lofexidine-matching sugar pill
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 18, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

NCT02846142
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PTI-428, Placebo, ethinyl estradiol and levonorgestrel
Drug · Other
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 18, 2026, 6:34 PM EDT